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Abstract
Background: Limited data suggest that fluorine-18 fluoro-2-deoxy-D-glucose (F-18 FDG) positron emission
tomography combined with computed tomography (PET/CT) scan may be useful for diagnosing infections of the
spine. Brucellar spondylodiskitis might be devastating and current imaging techniques lack sensitivity and
specificity. The aim of this prospective study was to determine the role of F-18 FDG PET/CT scan in the diagnosis of
brucellar spondylodiskitis and in monitoring the efficacy of its treatment.
Methods: Ten consecutive patients with brucellar spondylitis were prospectively evaluated with PET/CT. Baseline
evaluation included also magnetic resonance imaging (MRI) of the affected spine, indices of inflammation, the slide
agglutination test (SAT), and the standard hematology and biochemistry. All cases were treated with suitable
antibiotics until resolution or significant improvement of clinical and radiological (MRI) findings. Upon completion
of treatment, they were re-evaluated with follow-up PET/CT scan. The maximum standardized uptake values (SUV)
were measured and compared with SAT.
Results: In all patients there was an increased F-18 FDG activity in the infected spine region detected by the initial
MRI. F-18 FDG PET/CT provided additional information, compared to MRI, in 4 (40%) patients. More specifically it
revealed additional spine lesions (in 3 patients), lymphadenitis, arthritis, organomegaly, as well as new paravertebral
soft tissue involvement and epidural masses. This additional information had an impact on the duration of
treatment in these patients. At the end of treatment all patients had a complete clinical response; 5 patients had
positive serology, 6 patients had residual MRI findings, while 9 had a positive PET/CT but with significantly
decreased FDG uptake compared to baseline (median 2.6, range 1.4 – 4.4 vs. median 5.5, range 2.8 – 9.4, p = 0.005).
During the follow up period (median 12.5 months) no relapses have been observed. No significant association was
observed between the SUV and SAT.
Conclusions: Our study suggests that in patients with brucellar spondylodiskitis F-18 FDG PET/CT scan can provide
additional information on the spread of the infection, compared to MRI. Successful treatment is associated with a
significant decrease in SUVmax values; thus, PET/CT scan may be a complementary method for determining the
efficacy of treatment.
Keywords: Brucella, Spondylodiskitis, Positron emission tomography, Standardized uptake value
* Correspondence: savvasdoc@hotmail.com
1Pathophysiology Department, Medical School, National and Kapodistrian
University of Athens, 75, Mikras Asias, Athens 115 27, Greece
Full list of author information is available at the end of the article
© 2013 Ioannou et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Ioannou et al. BMC Infectious Diseases 2013, 13:73
http://www.biomedcentral.com/1471-2334/13/73
Background
Brucellosis is a common zoonosis caused by facultative
intracellular bacteria of the genus Brucella. Osteoarticular
involvement is the most common complication of the dis-
ease affecting one third of the patients [1]. The most
prevalent myoskeletal manifestation is spondylodiskitis, an
infection of the intervertebral disk and the adjacent
vertebrae, with or without associated epidural or psoas
abscesses. Brucellar spondylitis might be a devastating dis-
ease, since quite often, it is associated with neurological
and vascular complications, requires spinal surgery, and
results in permanent functional sequelae [2].
Although it was described back in 1932 [3], there are
still controversies regarding its management, such as the
best diagnostic strategy, the optimal antibiotic regimen,
the duration of treatment, and the criteria to consider
the disease as cured [4], since high relapse rates are a
major issue. Early and accurate diagnosis is important
for reducing permanent spinal deformity or neurological
defects. Multiplanar capability and superior tissue con-
trast make magnetic resonance imaging (MRI) the mo-
dality of first choice in the evaluation and follow-up of
brucellar spondylodiskitis [5,6]. However, the usefulness
of MRI only becomes apparent once a physician suspects
the existence of a target lesion. Moreover, residual MRI
findings at the end of treatment limit the use of MRI as
a criterion to consider the infection as cured.
During the last decade, the combination of fluorine-18
fluoro-2-deoxy-D-glucose (F-18 FDG) positron emission
tomography and computed tomography (PET/CT) scan
has emerged as a significant molecular imaging tech-
nique in clinical oncology and cancer research. Several
studies suggested that PET/CT might be a useful modal-
ity in patients with infectious spondylitis [4,7-9]. In the
current study, our aims were to define whether PET/CT
provides additional information, compared to traditional
imaging modalities, in the diagnosis of brucellar spon-
dylitis, and to determine whether it can guide physicians
to make decisions on the duration of treatment.
Methods
Patients and initial evaluation
Ten consecutive patients, who were diagnosed with brucel-
lar spondylitis at the Laikon General Hospital, in Athens
were enrolled in this study. The demographic variables
recorded at presentation were age, sex, occupation, type of
exposure to Brucella, associated illnesses, clinical presenta-
tion, and diagnostic delay. The baseline haematology stud-
ies included total and differential white blood cell counts,
haemoglobin levels, erythrocyte sedimentation rate (ESR),
C-reactive protein (CRP), the slide agglutination test (SAT)
and biochemistry profile. All patients underwent contrast-
enhanced MRI of the suspected spine region and were
subsequently (within 7 days) referred for a PET/CT scan
examination, in order to examine the distribution of active
inflammatory lesions and to search for other possible spine
lesions not detected earlier by MRI imaging. The study was
approved by the Ethics Committee of Athens Laikon Gen-
eral Hospital. All patients gave written informed consent
and consented to their individual data being published in
this article.
Diagnosis
The diagnosis of brucellosis was established by the clin-
ical findings compatible with brucellosis, positive SAT
(1:160 or higher), and/or by isolating Brucella species
from blood or bone marrow. Enzyme-linked immuno-
sorbent assay (ELISA) for Brucella-specific IgM and IgG
serum antibodies, as well as Coombs test were used as
additional diagnostic tools where available.
Imaging studies
Clinical diagnosis of spondylitis was initially estab-
lished by MRI. The main MR criteria for suspected
spondylodiskitis were hypointensity of disc and verte-
bral bodies on T1-weighted sequences, hyperintensity
on T2-weighted sequences and contrast enhancement
of the disc, adjacent vertebral bodies and involved
paraspinal tissues [10]. All MR images were evaluated
both independently and in consensus by 2 experi-
enced radiologists specializing in MRI of the muscu-
loskeletal system, who were blinded to the patients’
clinical history, laboratory, and pathological results.
F-18 FDG PET/CT protocol and interpretation
All patients fasted for at least 6 hours before the PET/CT
study. F-18 FDG was injected intravenously (370 –
555 MBq) and scanning began 60 min later. The serum
glucose levels were less than 160 mg/dl before injection.
No intravenous contrast was administered. Patients were
encouraged to void before imaging and scanned with a
combined FDG PET/CT scanner (Siemens Biograph 6 high
resolution PET/CT). Patients were imaged in the supine
position, with their arms placed above their heads when
possible. The acquisition time was 4 min per bed position.
CT scans began at the orbitomeatal line and progressed to
the upper thigh. PET followed immediately over the same
body region. The CT data were used for attenuation cor-
rection and images were reconstructed using a standard
ordered-subset expectation maximization (OSEM) algo-
rithm. All PET/CT studies were reviewed both independ-
ently and in consensus by 2 experienced nuclear medicine
physicians, who were also blinded to the clinical, patho-
logical, and imaging results. Positive finding was consid-
ered any increased uptake in the vertebral body(ies), disc
space(s) and/or surrounding soft tissues compared to the
uptake in uninvolved vertebral bodies, disc spaces or soft
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tissues respectively. The SUVmax of the abnormal areas
was recorded.
Treatment and follow-up period
All patients were treated and followed up according to
standard protocols used in our department [11], for at
least 6 months. A complete clinical, serology and imaging
(MRI) work-up was performed to assess the need for fur-
ther treatment. Each patient was treated until resolution
or significant improvement of clinical and radiological
findings. Upon completion of treatment, all patients were
re-evaluated with follow-up MRI and within 7 days with
PET/CT scanning. Complete remission, partial remission,
treatment failure, and relapse were defined as described
elsewhere [12].
Statistical analysis
The SUVmax was calculated at the baseline and follow up
PET/CT scan and the difference between the two was ana-
lyzed using a Wilcoxon paired test. The difference in me-
dian SUVmax in patients with resolution of MRI findings
at the end of treatment compared to those with residual
findings was determined using a Mann–Whitney U test.
In addition, Pearson correlation coefficient was used to
compare the SUVmax and SAT. A p value of less than
0.05 was considered statistically significant.
Results
Baseline characteristics
During the study period 10 patients (7 were males) with
brucellar spondylitis were enrolled. The median age was
58.5 years (range 37 – 87 years) (Table 1). Two patients
had an occupational exposure and all reported ingestion of
unpasteurized dairy products. At presentation, all patients
experienced fever and pain of the affected spinal region.
ESR ranged from 7 to 120 mm/h (median, 67 mm/h) and
CRP from 3.08 to 86.8 mg/L (median, 36.8 mg/L). An-
aemia was found in 3 (30%) patients and leukocytosis in 4
(40%). Abnormal liver function tests attributed to brucel-
losis were found in 2 (20%) patients.
SAT of initial samples was positive in 6 (60%) of the
10 patients. In the rest with negative SAT, a diagnostic
CT-guided biopsy of the affected spinal region was per-
formed. Biopsy results showed diffuse nonspecific in-
flammation with noncaseating granulomatous fibrous
deposits. Furthermore, in all the biopsy samples add-
itional microbiologic and histologic examinations were
performed which revealed the presence of Brucella sp.
ELISA was performed in 4 patients and revealed high
antibody levels in 2. Blood cultures were positive in 2
patients (20%) and all grew Brucella sp.; susceptibility
tests were not performed.
Imaging findings
All patients underwent an MRI scan at presentation, at
the vertebral level suspected to be infected by Brucella,
according to history and clinical findings. In all cases,
MRI had led to the strong suspicion of spondylodiskitis.
The vertebral level involved was lumbar or lumbo-sacral
in 8 (80%) cases and thoracic in 2 (20%) cases. Five
patients had paravertebral soft tissue involvement, while
one had epidural mass (Table 1).
Baseline PET/CT scan was performed subsequently in
all patients. In all 10 cases there was an increased F-18
FDG activity in the infected spine region, as diagnosed
by MRI (Table 1). In 4 patients the initial PET/CT scan
provided additional information compared to MRI, such
as lesions at different spine levels (3 patients), medias-
tinal lymphadenitis, arthritis, organomegaly, as well as
new paravertebral soft tissue involvement and epidural
masses. More specifically, additional spine lesions have
been detected: in patient 1 (T12 – L1, L1 – L2); in pa-
tient 2 (L4 – L5); and in patient 4 (T5 – T6) (Table 1)
(Figure 1a). These patients underwent additional MRI
scans of the affected new spine region which confirmed
the presence of spondylodiskitis. The median SUVmax
in the 14 affected vertebrae was 5.5 (range 2.8 – 9.4). An
SUVmax value ≥ 3.0 was observed in 13 of the 14
affected vertebrae.
Follow-up and outcome
The duration of treatment was based on clinical criteria
and imaging (MRI) re-evaluation. Only two patients
(Table 2, patients 5 and 9) had complete remission at
6 months and discontinued treatment. Six patients (Table 2,
patients 1, 2, 4, 7, 8, 10), including those with additional
PET/CT scan findings, had partial remission at 6 months,
and received antibiotic treatment for 12 months. More
specifically, they continued to experience pain of lesser se-
verity at the affected spinal areas with residual imaging
findings. One patient (Table 2, patient 3) discontinued
treatment at approximately 9 months due to immune
thrombocytopenia which was attributed to the antibiotics,
and patient 6 discontinued treatment at 11 months, when
complete remission was noted. At the end of treatment all
patients had complete remission of the disease with no re-
sidual paravertebral or epidural masses. After treatment
discontinuation all patients were followed up with regular
visits at the outpatient clinic for a median period of
12.5 months (range 8 – 27). No recurrences were observed
during this period; therefore, we consider that treatment
was successful in all of our study patients.
At the end of treatment all patients had negative indi-
ces of inflammation with normal full blood count and
liver function tests. In all 10 patients a follow-up PET/
CT scan was performed after treatment completion
(Table 2). Only one patient (Table 2, patient 5) had
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Table 1 Demographics, baseline laboratory, clinical and imaging findings among the 10 study patients with brucellar spondylitis
















1 M 59 106 63.3 1/10240 5.58 Back pain, fever Brucella sp. Spondylodiscitis L2 – L3, L5 –
S1, paravertebral masses
Spondylodiscitis T12 – L3, L5




2 M 61 14 10.1 1/10240 8.10 Back pain, fever (−) Spondylodiscitis T7 – T8,
paravertebral mass
Spondylodiscitis T7 – T8, L4 –
L5, paravertebral and epidural
masses
7.1 4.4
3 F 83 7 3.08 1/20480 5.93 Back pain, fever (−) Spondylodiscitis L2 – L3 Spondylodiscitis L2 – L3, 6.7
4 M 51 74 51.5 1/1280 13.30 Pack pain, fever (−) Spondylodiscitis L4 – L5,
paravertebral mass





5 M 53 80 38.6 < 1/160 9.30 Back pain, fever (−) Spondylodiscitis L4 – L5 Spondylodiscitis L4 – L5 6.9
6 F 71 120 86.8 1/2560 6.50 Back pain, fever Brucella sp. Spondylodiscitis L4 – L5,
paravertebral mass
Spondylodiscitis L4 – L5,
paravertebral mass
9.4
7 F 37 60 24 < 1/160 14.70 Back pain, fever (−) Spondylodiscitis T6 – T7 Spondylodiscitis T6 – T7,
hepatosplenomegaly
3.0
8 M 46 80 18.5 < 1/160 9.63 Back pain, fever (−) Spondylodiscitis L2 – L3,
epidural mass
Spondylodiscitis L2 – L3,
epidural mass
5.5
9 M 58 40 60 < 1/160 12.50 Back pain, fever (−) Spondylodiscitis L3 – L4 Spondylodiscitis L3 – L4 6.4
10 M 87 80 67 1/2560 11.40 Back pain, fever (−) Spondylodiscitis L1 – L2, L4 –
L5, paravertebral mass
Spondylodiscitis L1 – L2, L4 –
L5, paravertebral mass
5.2 6.0
NOTES. All patients provided written consent to publish these details. Pt: patient number, ESR: erythrocyte sedimentation rate (normal value, 40 mm/hour), CRP: C-reactive protein (normal values < 5 mg/L), WBC: white
blood count, SAT: slide agglutination test (normal values < 1/160), MRI: magnetic resonance imaging, F-18 FDG PET/CT: fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography combined with computed



















Figure 1 (See legend on next page.)
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negative PET/CT scan findings; in the rest 9 patients the
PET/CT scan findings were diagnosed as positive. How-
ever, a visual decrease in the F-18 FDG uptake compared
to the uninvolved tissues, with median SUVmax 2.6
(range 1.4 – 4.4) was observed in the 14 infected verte-
brae (Figure 1b). An SUVmax value > 3.0 was observed
in only 3 of the 14 affected vertebrae. Complete reso-
lution of MRI findings occurred in 4 patients (Table 2,
patients 5, 7, 8, 9) at the time of the last follow-up.
Three of these patients had positive PET/CT scan find-
ings; SUVmax was significantly lower in patients with
resolution of MRI findings, compared to patients with
residual MRI findings (median SUVmax 2.0 vs. 3.05, p =
0.05). No significant association was observed between
the SUVmax and SAT values (p > 0.05).
Discussion
In the present, it was demonstrated that PET/CT scan
may provide useful information in the management of
brucellar spondylodiskitis. All patients enrolled had posi-
tive PET/CT scan findings at the time of diagnosis, with
high uptake of FDG within the infected tissue, as SUV-
max values were as high as 9.4, and 13 of the 14 infected
vertebrae had SUVmax > 3.0. More importantly, in 4
(40%) of our patients, PET/CT scan provided additional
information on the spread of the infection, beyond the
initial lesion detected by MRI. This is particularly im-
portant as MRI of the whole spine is not logistically feas-
ible and other noncontiguous foci of spinal infection can
be missed, exposing patients to the risk of devastating
neurological complications. Moreover, brucellosis is a
systematic disease affecting many organs and systems;
therefore, PET/CT scan is suitable to define the real ex-
tend of the disease, beyond the affected spine.
Our data are in accordance with those of other studies
that demonstrated high sensitivity and specificity of
PET/CT scan in detecting infectious processes of the
spine [13,14]. A recent review article [15] highlights the
clinical role of this technique in diagnosing spinal infec-
tions, with sensitivities ranging from 94% to 100% and
specificities ranging from 87% to 100%. Moreover, in a
recent retrospective study [16] PET/CT had a strong im-
pact on the clinical management of 52% of patients with
infectious spondylitis.
Usefulness of PET/CT in monitoring the efficacy of
treatment was less clear; at the end of treatment only 1 pa-
tient had a negative PET/CT while 4 patients had a nega-
tive MRI of the affected spine. Successful treatment
resulted+ in a significant decrease in SUVmax values, while
patients with no residual MRI findings had significantly
(See figure on previous page.)
Figure 1 A. Sagittal (top) and coronal images of baseline PET/CT scan. Detailed legend: These images of patient no 4 show abnormal
hypermetabolism at the left acromioclavicular joint, and at T6 and L5 vertebrae, along with paravertebral soft tissue involvement. Initial MRI
evaluation of the lumbar spine of the same patient revealed only the lesion at the area of L4 – L5 vertebrae with paravertebral mass. B. Follow-
up PET/CT scan after treatment. Detailed legend: These images of patient no 4 post-treatment demonstrate decreased FDG uptake at T6 and L5
vertebrae, and no uptake at the paravertebral tissues.
























1 12 40 5.00 1/320 4.70 (−) L5 – S1 L2 – L3, L5 – S1 3.2 2.6 27
2 12 10 5.00 1/680 6.50 (−) T7 – T8 T7 – T8, L4 – L5 3.3 2.0 13
3 9 5 3.08 1/ 10240 4.43 (−) L2 – L3 L3 2.9 21
4 12 35 10.00 1/320 6.65 (−) L4 – L5 L5 T6 2.6 2.9 10
5 6 15 2.97 < 1/160 7.24 (−) (−) (−) 0 9
6 11 15 2.97 1/320 5.15 Back pain on effort L4 – L5 L4 – L5 2.7 8
7 12 17 3.08 < 1/160 7.85 Pain on weather
changes
(−) T7 2.0 17
8 12 20 4.10 < 1/160 8.90 (−) (−) L3 2.0 11
9 6 14 5.00 < 1/160 7.70 (−) (−) L3 3.0 21
10 12 23 5.00 < 1/160 4.80 Back pain on effort L4 – L5 L1 – L2, L4 – L5 2.9 4.4 12
NOTES. Pt: patient number, ESR: erythrocyte sedimentation rate (normal value, 40 mm/hour), CRP: C-reactive protein (normal values < 5 mg/L), WBC: white blood
count, SAT: slide agglutination test (normal values < 1/160), MRI: magnetic resonance imaging, F-18 FDG PET/CT: fluorine-18 fluoro-2-deoxy-D-glucose positron
emission tomography combined with computed tomography scan, SUVmax: maximum standard uptake value.
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lower SUVmax compared to those with residual MRI find-
ings. As expected, after successful treatment virtually all
patients had negative indices of inflammation.
MRI is the imaging modality of choice for the diagno-
sis of brucellar spondylodiskitis as it has high sensitivity
and specificity, but it has technical limitations: it is sen-
sitive to motion degradation, so that patients with move-
ment disorders may not be suitable candidates; certain
metallic implants are contraindications for this modality;
it cannot always help distinguish spondylitis from severe
degenerative arthritis. Moreover, physicians order MRI
scans only of the spinal region with the suspected target
lesion. However, in published series of patients with bru-
cellar spondylodiskitis a substantial percentage of up to
9% [2,17] had noncontiguous multifocal spinal involve-
ment, which can be missed if only one spinal region is
assessed. Therefore, in every case of suspected brucellar
spondylitis the whole spine should be evaluated with MRI,
but this is logistically difficult in the everyday practice.
Several clinical studies [7,13,18,19] have reported the
effectiveness of PET in imaging musculoskeletal infec-
tions. PET allows rapid imaging within 1 h after the
FDG-injection [18]. Additionally, FDG-PET shows a high
spatial resolution. This can be helpful in assessing the
paravertebral abscesses in spondylodiskitis. On the other
hand, FDG-PET/CT is not always possible to distinguish
between spondylodiskitis and degenerative changes in
the vertebral endplates. Stumpe et al., found that none
of the patients in their study with degenerative disc dis-
ease had increased uptake on PET imaging [19]. Con-
versely, Rosen et al. found increased disc activity in
those with degenerative changes [20]. In another study,
Schmitz et al. found that all the cases in their series that
had histopathological confirmation of infection had posi-
tive FDG PET imaging [18].
The optimal duration of treatment of brucellar spon-
dylodiskitis remains a controversial issue. Serology and
imaging are not always helpful, as residual MRI findings
are present long after successful treatment [21]. We
consider that all our cases were treated successfully,
because no relapses have been observed during the fol-
low up. Nevertheless, at the end of treatment 5 of the 10
patients had a high SAT titer, while only 4 had a nega-
tive MRI of the affected spine. Successful treatment
resulted in a significant decrease in median SUVmax
values from 5.5 to 2.6 (Figure 2), while patients with no
residual MRI findings had significantly lower SUVmax
compared to those with residual MRI findings. The rea-
son of FDG uptake, even in patients with no residual
MRI findings, and despite successful treatment is not
clear. One possible explanation is that even successful
treatment does not eliminate the infection but it turns it
to a latent infection of the spine. Actually, recent studies
have shown that long after discontinuation of treatment
serology and serum PCR for Brucella remain positive
despite the lack of clinical symptoms [22,23].
Our study did not detect an SUVmax cut off value
for successfully treated patients. However, an SUVmax
value > 3.0 was observed in only 3 of the 14 affected verte-
brae after successful treatment compared to 13 before treat-
ment initiation. These findings suggest that SUVmax < 3.0
might be indirect evidence of successful treatment, along
with negative indices of inflammation, resolution or im-







Baseline SUV Post-Treatment SUV
Figure 2 SUVmax at baseline PET/CT scans, before treatment initiation vs. post-treatment PET/CT scan, showing a significant
decrease (p = 0.005).
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This study is limited by the small number of patients
and the lack of control group, because brucellar spondy-
lodiskitis is a rather rare disease. However, we have
shown that in patients with brucellar spondylodiskitis
PET/CT scan provided additional information on the
spread of the infection, beyond the initial lesion detected
by MRI. Moreover, our study showed that successful
treatment is associated with a significant decrease in
SUVmax values; thus, PET/CT scan may be a comple-
mentary method to MRI for determining the efficacy of
treatment. More studies are clearly required to identify
the role of PET/CT imaging in the management of
patients with brucellar spondylitis.
Conclusions
To our knowledge, this is the only study to date to
evaluate the role of F-18 FDG PET/CT scan in the diag-
nosis and efficacy of treatment of patients with brucellar
spondylitis. Brucellar spondylitis might be a devastating
disease, since quite often, it is associated with neuro-
logical and vascular complications, requires spinal sur-
gery, and results in permanent functional sequelae. MRI
remains the imaging procedure of choice for the evalu-
ation and assessment of therapy of this complication.
However, two interesting findings emerge from our study:
firstly, F-18 FDG PET/CT scan can provide additional in-
formation on the spread of brucellar spondylitis, com-
pared to MRI; secondly, successful treatment is associated
with a significant decrease in SUVmax values. Therefore,
PET/CT scan may be useful in assessing the efficacy of
treatment and the need for further antimicrobial chemo-
therapy. Further research is necessary to better under-
stand the role and impact of PET/CT imaging in the
management of patients with brucellar spondylitis.
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